Abstract
Radioimmunotherapy is a well-known treatment for non-Hodgkin's lymphoma. (90)yttrium (Y)-ibritumomab-tiuxetan consists of a radioisotope conjugated to a monoclonal anti-cluster of differentiation 20 antibody, which is targeted against B-lymphocytes. Initially the treatment indication was relapse of low-grade non-Hodgkin's lymphoma. However, (90)Y-ibritumomab-tiuxetan has later been used in clinical trials in the treatment of other types of non-Hodgkin's lymphoma and prior to stem cell transplantation. Based on the literature this systematic review aims to throw light on the future possibilities of radioimmunotherapy.
| Translated title of the contribution | Indications for radioimmunotherapy for patients with non-Hodgkin's lymphoma |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 173 |
| Issue number | 20 |
| Pages (from-to) | 1417-21 |
| Number of pages | 5 |
| ISSN | 0041-5782 |
| Publication status | Published - 2011 |